In vivo electroporation enhances immunogenicity and protection against influenza A virus challenge of an M2e-HSP70c DNA vaccine

Virus Research

Volumn 167, Issue 2, 2012, Pages 219-225

  Jazi, Mohammad Hossein Zabeh ^b   Dabaghian, Mehran ^b   Tebianian, Majid ^c   Gharagozlou, Mohammad Javad ^b   Ebrahimi, Seyyed Mahmoud ^a  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF TEHRAN   (Iran)

^c RAZI VACCINE AND SERUM RESEARCH INSTITUTE   (Iran)

Author keywords

DNA vaccine; HSP70c; In vivo electroporation; Influenza A virus; M2e

Indexed keywords

COMPLEMENTARY DNA; DNA VACCINE; EXTRACELLULAR DOMAIN OF M2 HEAT SHOCK PROTEIN 70C DNA VACCINE; HEAT SHOCK PROTEIN 70; INFLUENZA VACCINE; PLASMID VECTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTROPORATION; EMBRYO; FEMALE; FOOT PAD; GENE CONSTRUCT; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; IN VIVO STUDY; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; LETHAL DOSE; LUNG HOMOGENATE; MAMMAL CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSIENT TRANSFECTION; VIRUS IMMUNITY; VIRUS LOAD; WESTERN BLOTTING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; CELL LINE; ELECTROPORATION; FEMALE; HSP70 HEAT-SHOCK PROTEINS; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; VACCINES, DNA; VIRAL MATRIX PROTEINS;

ANIMALIA; INFLUENZA A VIRUS; MAMMALIA; MUS; ORTHOMYXOVIRIDAE;

EID: 84863863794     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2012.05.002     Document Type: Article

References (42)

1. Abdian N., Gholami E., Zahedifard F., Safaee N., Rafati S. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis. Experimental Parasitology 2011, 127:627-636.
2. Betakova T. M2 protein - a proton channel of influenza A virus. Current Pharmaceutical Design 2007, 13:3231-3235.
3. Bodles-Brakhop A.M., Heller R., Draghia-Akli R. Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments. Molecular Therapy 2009, 17:585-592.
4. Bolhassani A., Rafati S. Heat-shock proteins as powerful weapons in vaccine development. Expert Review of Vaccines 2008, 7:1185-1199.
5. Doherty P.C., Turner S.J., Webby R.G., Thomas P.G. Influenza and the challenge for immunology. Nature Immunology 2006, 7:449-455.
6. Du L., Zhou Y., Jiang S. Research and development of universal influenza vaccines. Microbes and Infection 2010, 12:280-286.
7. Ebrahimi S.M., Tebianian M. Heterologous expression, purification and characterization of the influenza A virus M2e gene fused to Mycobacterium tuberculosis HSP 70359-610 in prokaryotic system as a fusion protein. Molecular Biology Reports 2010, 37:2877-2883.
8. Ebrahimi S.M., Tebianian M. Influenza A viruses: why focusing on M2e-based universal vaccines. Virus Genes 2011, 42:1-8.
9. Ebrahimi S.M., Tebianian M., Toghyani H., Memarnejadian A., et al. Cloning, expression and purification of the influenza A (H9N2) virus M2e antigen and truncated Mycobacterium tuberculosis HSP70 as a fusion protein in Pichia pastoris. Protein Expression and Purification 2010, 70:7-12.
10. Ebrahimi S.M., Ziapour S., Tebianian M., Dabaghian M., Mohammadi M. Study of infection with an Iranian field-isolated H9N2 avian influenza virus in vaccinated and unvaccinated Japanese quail. Avian Diseases 2011, 55:195-200.
11. Fan J., Liang X., Horton M.S., Perry H.C., Citron M.P., et al. Preclinical study of influenza virus A M2 peptide conjugates vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004, 22:2993-3003.
12. Fiers W., De Filette M., Birkett A., Neirynck S., Min Jou W. A universal human influenza A vaccine. Virus Research 2004, 103:173-176.
13. Fiers W., De Filette M., Bakkouri K.E., Schepens B., et al. M2e-based universal influenza A vaccine. Vaccine 2009, 27:6280-6283.
14. Grandea III Andres G., Olsena Ole A., Coxa Thomas C., et al. Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:12658-12663.
15. Huang H.N., Li T.L., Chan Y.L., Chen C.L., et al. Transdermal immunization with low-pressure-gene-gun mediated chitosan-based DNA vaccines against Japanese encephalitis virus. Biomaterials 2009, 30:6017-6025.
16. Huleatt J.W., Valerian N., Priyanka D., Yan H., Duane H., Andrea J., et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008, 26:201-214.
17. Jameson J., Cruz J., Ennis F.A. Human cytotoxic T-lymphocyte repertoire to influenza A viruses. Journal of Virology 1998, 72:8682-8689.
18. Jegerlehner A., Tissot A., Lechner F., Sebbel P., Erdmann I., Kundig T., et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 2002, 20:3104-3112.
19. Kutzler M.A., Weiner D.B. DNA vaccines: ready for prime time?. Nature Reviews Genetics 2008, 9:776-788.
20. Laddy D.J., Yan J., Kutzler M. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS ONE 2008, 3:e2517.
21. Laemmli U.K. Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 1970, 277:680-685.
22. Lamb R.A., Zebedee S.L., Richardson C.D. Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 1985, 40:627-633.
23. Li X., Yang X., Li L., Liu H., et al. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 gene enhanced potency of HPV DNA vaccine. Vaccine 2006, 24:3321-3331.
24. Liu W., Li H., Chen Y.H. N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication. FEMS Immunology and Medical Microbiology 2003, 35:141-146.
25. Luckay A., Sidhu M.K., Kjeken R. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. Journal of Virology 2007, 81:5257-5269.
26. Luo M., Tao P., Li J., et al. Immunization with DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice. Journal of Virological Methods 2008, 154:121-127.
27. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Min Jou W., Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2e protein. Nature Medicine 1999, 5:1157-1163.
28. Palese P. Making better influenza virus vaccines?. Emerging Infectious Diseases 2006, 12:61-65.
29. Pan Z., Zhang X., Geng S., et al. Priming with a DNA vaccine delivered by attenuated Salmonella typhimurium and boosting with a killed vaccine confers protection of chickens against infection with the H9 subtype of avian influenza virus. Vaccine 2008, 27:1018-1023.
30. Pinto L.H., Lamb R.A. The M2 proton channels of influenza A and B viruses. Journal of Biological Chemistry 2006, 281:8997-9000.
31. Reed L.J., Muench H.A. Simple method for estimating fifty per cent endpoints. American Journal of Hygiene 1938, 27:493-497.
32. Saelens X. The influenza matrix protein 2 as vaccine target. Future Virology 2008, 3:167-178.
33. Schotsaert.M., De Filette M., Fiers W., Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Review of Vaccines 2009, 8:499-508.
34. Shedlock D.J., Weiner D.B. DNA vaccination: antigen presentation and the induction of immunity. Journal of Leukocyte Biology 2000, 68:793-806.
35. Sprecher E., Becker Y. Herpes simplex virus type 1 pathogenicity in footpad and ear skin of mice depends on langerhans cell density, mouse genetics, and virus strain. Journal of Virology 1987, 61:2515-2522.
36. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annual Review of Immunology 2002, 20:395-425.
37. Subbarao K., Joseph T. Scientific barriers to developing vaccines against avian influenza viruses. Nature Reviews Immunology 2007, 7:267-278.
38. Ulmer J.B. Influenza DNA vaccines. Vaccine 2002, 20:S74-S76.
39. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259:1745-1749.
40. Wang S., Zhang C., Zhang L., et al. The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods. Vaccine 2008, 6:2100-2110.
41. Zhang W., Li W., Li Y., et al. Immune effects against influenza A virus and a novel DNA vaccine with co-expression of haemagglutinin- and neuraminidase-encoding genes. Journal of Medical Microbiology 2006, 58:845-854.
42. Zhao G., Lin Y., Du L. An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virology Journal 2010, 7:9.